This article is a narrative review that looks at the role of MicroRNAs in Melanoma. The study does not report a specific sample size, population, or clinical setting. Because it is a review rather than a new clinical trial, it summarizes existing information rather than testing a specific treatment or intervention. The authors discuss MicroRNAs as a topic of interest for this condition. No primary or secondary outcomes were measured in a traditional sense, and no specific results or safety data were reported in this text. Readers should understand that this is a descriptive overview. It is important to note that this type of publication does not provide new evidence to change medical practice. The information presented is based on what has been published previously. There are no reported adverse events or discontinuations because no new patients were enrolled. This review helps explain the current state of knowledge but does not offer new proof of benefit or harm. Patients and doctors should rely on established guidelines while keeping an eye on emerging research topics like MicroRNAs.
Narrative review discusses MicroRNAs in melanoma without reported outcomes or safety dataA review explores how MicroRNAs might relate to Melanoma
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Note that this narrative review lacks reported outcomes or safety data for MicroRNAs in melanoma.
This source is a narrative review focusing on MicroRNAs in the context of melanoma. The authors provide a qualitative discussion of the subject matter rather than presenting quantitative trial data or pooled effect sizes. The review does not include specific sample sizes, intervention details, or comparator groups in its reporting.
The text notes that primary outcomes and secondary outcomes were not reported. Similarly, safety information including adverse events, serious adverse events, discontinuations, and tolerability is not reported. The review does not specify a follow-up duration or setting for the discussed MicroRNAs.
Limitations acknowledged by the authors include the absence of reported data on population characteristics and study design specifics. Consequently, the practice relevance of these findings remains unclear as no specific recommendations or certainty notes are provided. The evidence presented is limited to the qualitative scope of the narrative review.
What this means for you:
This narrative review discusses MicroRNAs in Melanoma but offers no new clinical evidence or safety data. More on Melanoma
Narrowband UVB remains first-line phototherapy for vitiligo, with JAK inhibitors emerging as adjuncts
New light therapies and skin grafts offer hope for vitiligo patients
This narrative review synthesizes current evidence on phototherapy for vitiligo, highlighting narrowband UVB as the mainstay. Excimer lasers…
A review of treatments for vitiligo highlights options like narrowband ultraviolet B light, excimer therapy, and cellular grafting that may …
Meta-analysis finds modest melanoma risk increase among infertile women using fertility treatments
Fertility Drugs Linked to Slight Rise in Melanoma Risk
This systematic review and meta-analysis evaluated melanoma incidence in infertile women exposed to fertility treatments compared to untreat…
A large review finds fertility drugs may raise melanoma risk slightly, but the increase is small and more research is needed.
TIL therapy and engineered viral vector immunotherapies show pooled ORR of 37.8% in advanced melanoma
First new analysis in years shows TIL therapy response rates for advanced melanoma
This Bayesian meta-analysis synthesizes data from 13 eligible studies on TIL therapy and engineered viral vector immunotherapies for advance…
A Bayesian meta-analysis of 13 studies finds TIL therapy yields a 49% response rate in advanced melanoma, with moderate certainty for respon…
Systematic Review: Intercellular Mitochondrial Transfer in Melanoma Progression and Resistance
Mitochondrial Transfer Fuels Melanoma Resistance and Spread
This systematic review examines the role of intercellular mitochondrial transfer in melanoma. The authors find that this process contributes…
A systematic review reveals that intercellular mitochondrial transfer helps melanoma resist therapies and spread, but may also suppress tumo…
View Original Abstract ↓
Melanoma, a highly malignant form of skin cancer, continues to rise in incidence worldwide. Early diagnosis and accurate prognostic assessment are critical to reducing melanoma-related mortality rates. MicroRNAs (miRNAs), a class of non-coding RNAs approximately 22 nucleotides in length, play pivotal roles in melanoma initiation, progression, invasion, and metastasis by regulating the expression of target genes. Beyond their cell-intrinsic functions, miRNAs are increasingly recognized as critical regulators of the tumor immune microenvironment (TIME). They modulate anti-tumor immune responses by influencing immune checkpoint expression, immune cell recruitment and function, and intercellular communication via extracellular vesicles (EVs). This comprehensive review explores the multifaceted functions of miRNAs in melanoma, highlighting their potential as diagnostic markers, prognostic indicators, and predictors of therapeutic response. It also addresses current research challenges and explores future directions, including the integration of AI-powered spatial transcriptomics to decipher the complex, context-dependent networks of miRNAs within the TIME, offering a theoretical foundation and novel insights for precision medicine in melanoma treatment.
Late-onset rheumatoid arthritis shows higher DAS28 scores and lower remission rates compared to young-onset disease in a meta-analysis
Meta-analysis compares treatment outcomes in older versus younger rheumatoid arthritis patients
Related in Rheumatology
Long-term personalized exercise therapy shows potential cost-effectiveness for patients with axial spondyloarthritis
Personalized exercise therapy shows promise for axial spondyloarthritis patients
Researchers evaluated the cost-utility of long-term, personalized exercise therapy compared to usual care in patients with axial spondyloart…
New research looks at whether personalized, long-term exercise programs are a cost-effective way to manage severe axial spondyloarthritis.
EmiratesMEDs competency framework establishes 9 thematic roles and 14 EPAs for UAE medical education
New UAE framework sets 85 competencies for medical graduates
This guideline outlines the EmiratesMEDs competency framework designed to harmonize undergraduate medical education in the United Arab Emira…
A national competency framework for UAE medical graduates defines 85 skills and 14 clinical tasks to standardize education.
Esketamine significantly reduces postoperative anxiety (SMD -1.23) and depressive symptoms (SMD -0.92) in adult patients
Esketamine reduces anxiety and depression after surgery
This meta-analysis of 1,312 adults undergoing general anesthesia found that esketamine significantly reduced both anxiety and depression pos…
New data shows esketamine can significantly lower feelings of anxiety and depression in adults following surgery.
Machine learning and postoperative indicators improve AUC for predicting anastomotic leak in gastric cancer surgery
Machine Learning Models May Better Predict Gastric Cancer Complications
This systematic review and meta-analysis of 18 studies involving 15,783 patients evaluated risk prediction models for anastomotic leak. The …
New analysis shows machine learning models may offer better accuracy in predicting surgical complications for patients with gastric cancer.
From Other Specialties
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …
Rapid advancements in imaging and blood-based biomarkers are transforming the diagnosis and management of ADRD
New guidelines help doctors tell delirium from dementia
This clinical guideline provides a narrative review on the evolving diagnostic and treatment landscape for Alzheimer's disease and related d…
Delirium is acute and fluctuating; dementia is chronic. New guidelines help doctors tell them apart.
ACTH and vigabatrin achieved full seizure control in a patient with Ververi-Brady syndrome
ACTH and Vigabatrin Show Promise for Rare Epilepsy Syndrome
This case report describes a 5-month-old male infant with Ververi-Brady syndrome and infantile epileptic spasms syndrome. The patient achiev…
A new gene variant linked to Ververi-Brady syndrome showed positive results when treated with a combination of ACTH and vigabatrin.